117 related articles for article (PubMed ID: 18091378)
1. YKL-40 expression in benign and malignant lesions of the breast: a methodologic study.
Roslind A; Johansen JS; Junker N; Nielsen DL; Dzaferi H; Price PA; Balslev E
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):371-81. PubMed ID: 18091378
[TBL] [Abstract][Full Text] [Related]
2. Subcellular localization of YKL-40 in normal and malignant epithelial cells of the breast.
Roslind A; Balslev E; Kruse H; Staergaard B; Horn T
Ultrastruct Pathol; 2008; 32(3):101-6. PubMed ID: 18570155
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
Kim SH; Das K; Noreen S; Coffman F; Hameed M
World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
[TBL] [Abstract][Full Text] [Related]
4. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation.
Roslind A; Johansen JS
Methods Mol Biol; 2009; 511():159-84. PubMed ID: 19347297
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of the inflammatory protein YKL-40 in precancers of the breast.
Qin W; Zhu W; Schlatter L; Miick R; Loy TS; Atasoy U; Hewett JE; Sauter ER
Int J Cancer; 2007 Oct; 121(7):1536-42. PubMed ID: 17565739
[TBL] [Abstract][Full Text] [Related]
6. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
[TBL] [Abstract][Full Text] [Related]
7. Immunocytochemical identification of cell types in benign and malignant breast diseases: variations in cell markers accompany the malignant state.
Rudland PS; Leinster SJ; Winstanley J; Green B; Atkinson M; Zakhour HD
J Histochem Cytochem; 1993 Apr; 41(4):543-53. PubMed ID: 8450194
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of clusterin in human breast carcinoma.
Redondo M; Villar E; Torres-Muñoz J; Tellez T; Morell M; Petito CK
Am J Pathol; 2000 Aug; 157(2):393-9. PubMed ID: 10934144
[TBL] [Abstract][Full Text] [Related]
9. YKL-40 protein expression in normal adult human tissues--an immunohistochemical study.
Ringsholt M; Høgdall EV; Johansen JS; Price PA; Christensen LH
J Mol Histol; 2007 Mar; 38(1):33-43. PubMed ID: 17242979
[TBL] [Abstract][Full Text] [Related]
10. YKL-40 protein levels and clinical outcome of human endometrial cancer.
Peng C; Peng J; Jiang L; You Q; Zheng J; Ning X
J Int Med Res; 2010; 38(4):1448-57. PubMed ID: 20926018
[TBL] [Abstract][Full Text] [Related]
11. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer.
Junker N; Johansen JS; Andersen CB; Kristjansen PE
Lung Cancer; 2005 May; 48(2):223-31. PubMed ID: 15829322
[TBL] [Abstract][Full Text] [Related]
12. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV; Johansen JS; Price PA
Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
[TBL] [Abstract][Full Text] [Related]
13. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
[TBL] [Abstract][Full Text] [Related]
14. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
15. Association between YKL-40 and adult primary astrocytoma.
Zhang W; Kawanishi M; Miyake K; Kagawa M; Kawai N; Murao K; Nishiyama A; Fei Z; Zhang X; Tamiya T
Cancer; 2010 Jun; 116(11):2688-97. PubMed ID: 20499402
[TBL] [Abstract][Full Text] [Related]
16. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer.
Wang D; Zhai B; Hu F; Liu C; Zhao J; Xu J
PLoS One; 2012; 7(12):e51127. PubMed ID: 23227243
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues.
Yang GF; Cai PY; Li XM; Deng HX; He WP; Xie D
Ai Zheng; 2009 Feb; 28(2):142-5. PubMed ID: 19550125
[TBL] [Abstract][Full Text] [Related]
18. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
19. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer.
Johansen JS; Cintin C; Jørgensen M; Kamby C; Price PA
Eur J Cancer; 1995; 31A(9):1437-42. PubMed ID: 7577068
[TBL] [Abstract][Full Text] [Related]
20. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.
Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
Tumour Biol; 2014 Jan; 35(1):277-86. PubMed ID: 23918300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
